Separately, HC Wainwright upped their price target on shares of Minerva Neurosciences from $8.00 to $11.00 and gave the company a “neutral” rating in a report on Wednesday, August 2nd.
Minerva Neurosciences Price Performance
Institutional Trading of Minerva Neurosciences
A number of hedge funds and other institutional investors have recently made changes to their positions in the business. JPMorgan Chase & Co. lifted its stake in Minerva Neurosciences by 150,466.7% in the 2nd quarter. JPMorgan Chase & Co. now owns 4,517 shares of the biopharmaceutical company’s stock valued at $41,000 after acquiring an additional 4,514 shares in the last quarter. UBS Group AG lifted its position in shares of Minerva Neurosciences by 914.5% during the 3rd quarter. UBS Group AG now owns 5,732 shares of the biopharmaceutical company’s stock worth $53,000 after buying an additional 5,167 shares during the last quarter. Renaissance Technologies LLC lifted its position in shares of Minerva Neurosciences by 8.3% during the 4th quarter. Renaissance Technologies LLC now owns 110,300 shares of the biopharmaceutical company’s stock worth $175,000 after buying an additional 8,500 shares during the last quarter. Geode Capital Management LLC raised its position in Minerva Neurosciences by 26.5% in the second quarter. Geode Capital Management LLC now owns 51,964 shares of the biopharmaceutical company’s stock valued at $475,000 after purchasing an additional 10,900 shares during the last quarter. Finally, Virtu Financial LLC bought a new position in shares of Minerva Neurosciences during the second quarter worth about $192,000. 55.11% of the stock is currently owned by institutional investors and hedge funds.
Minerva Neurosciences Company Profile
Minerva Neurosciences, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone (MIN-101) for the treatment of negative symptoms in patients with schizophrenia, currently submitted an New Drug Application (NDA); and MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson's disease and other neurodegenerative disorders.
- Five stocks we like better than Minerva Neurosciences
- Conference Calls and Individual Investors
- MarketBeat Week in Review – 11/6 – 11/10
- What is a Death Cross in Stocks?
- Data giants MongoDB and Snowflake just got upgraded
- Dividend Payout Ratio Calculator
- Plug Power at tipping point; it’s make or break time for hydrogen
Receive News & Ratings for Minerva Neurosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Minerva Neurosciences and related companies with MarketBeat.com's FREE daily email newsletter.